INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines

Pomerantz LLP announced that a class-action lawsuit has been filed against Replimune Group (NASDAQ: REPL). The announcement provides no allegations, claimed damages, financial figures, or case-specific details, but litigation creates a potential reputational and financial overhang for the biotech company.